SIC
ELDN icon

SJS Investment Consulting’s Eledon Pharmaceuticals ELDN Stock Holding History

SJS Investment Consulting’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$339 Buy
86
+77
+856% +$280 ﹤0.01% 2367
2026
Q1 		$28 Buy
+9
New +$21 ﹤0.01% 2336

Other funds holding ELDN

TCM
Triumph Capital Management Denver, Colorado $552M AUM 20.75% 1-Year Est. Return
PAM
Prodigy Asset Management Omaha, Nebraska $332M AUM 10.57% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $43.3B AUM 29.3% 1-Year Est. Return
PNFS
PW Nova Financial Services Newtown, Pennsylvania $466M AUM
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
HFS
Howard Financial Services Dallas, Texas $1B AUM 20.02% 1-Year Est. Return
KPWS
Kestra Private Wealth Services Austin, Texas $9.1B AUM 32.09% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
RZH
Relyea Zuckerberg Hanson Stamford, Connecticut $1.2B AUM 28.45% 1-Year Est. Return

SJS Investment Consulting's ELDN Position: Q2 2026 in Review

SJS Investment Consulting increased its Eledon Pharmaceuticals (ELDN) stake by 856% in Q2 2026, buying an estimated $280 and bringing the position to 86 shares worth $339. The position accounts for ﹤0.01% of the portfolio, ranked #2367.

SJS Investment Consulting first reported a position in ELDN in Q1 2026 and has held it in 2 quarters since. 38 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

  • SJS Investment Consulting held 86 shares of Eledon Pharmaceuticals worth $339 as of Q2 2026.
  • SJS Investment Consulting bought 77 Eledon Pharmaceuticals shares in Q2 2026, an estimated $280.
  • Eledon Pharmaceuticals made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #2367 holding.
  • SJS Investment Consulting first reported a position in Eledon Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 38 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.